2 SCIENTIFIC SESSIONS DAILY NEWS | Day 3 Monday, Nov. 18, 2024 Today at Sessions Late-Breaking Science LBS.06: Building on the Four Pillars: Novel Trials of Medical Therapy for Heart Failure 8-9:15 a.m. | Main Event I • Myeloperoxidase Inhibition With Mitiperstat in Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Primary Results From the ENDEAVOR Randomized Clinical Trial • Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial • Novel Bumetanide Nasal Spray (BNS) Demonstrates Safety, Tolerability and Equivalent Efficacy Compared to Intravenous and Oral Bumetanide (RSQ-777-02) • Sodium Zirconium Cyclosilicate and MRA Optimization in Heart Failure With Reduced Ejection Fraction and Hyperkalemia: Main Results From REALIZE-K Randomized Controlled Trial LBS.07: Revolutionizing AF Management: Cutting-Edge Approaches 9:45-11 a.m. | Main Event I • Comparison of Linear Ablation Plus Pulmonary Vein Isolation vs. Pulmonary Vein Isolation Alone for Persistent Atrial Fibrillation: Results From the PROMPT-AF Randomized Trial • Cryoballoon Ablation vs. Radiofrequency Ablation in Patients With Persistent Atrial Fibrillation (CRRF-PeAF): A Prospective, Multicenter, Randomized, Noninferiority Clinical Trial • Randomized Controlled Trial of Metformin and Lifestyle/ Risk Factor Modification for Upstream Prevention of Atrial Fibrillation Progression: The Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF) Trial • Aggressive Risk Factor Reduction Study for Atrial Fibrillation (ARREST-AF) Implications for Ablation Outcomes: A Randomized Clinical Trial LBS.08: New Targets and New Treatments: Advances in Lipid Therapeutics 1:30-2:45 p.m. | Main Event I • ALPACAR Phase 2 Trial of Zerlasiran: Multiple Doses of a Short-Interfering RNA Targeting Lipoprotein(a) Over 60 weeks. • A Randomized Phase 2 Trial of Muvalaplin: An Oral Disrupter of the Assembly of Lipoprotein(a) Particles (KRAKEN) • Safety and Efficacy of Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia (BROOKLYN) Featured Science FS.04: Vascular Outcomes in the Spotlight 8-9:15 a.m. | S100A • Geographical Variations of Treatment Disparities Between Black and White Patients With Peripheral Artery Disease Across the United States • Anatomically Directed Lower Extremity Gene Therapy for Ulcer Healing: A Double Blind, Randomized, Placebo Controlled Study (Legend 1 Trial) • Bempedoic Acid and Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: New Insights From the CLEAR OUTCOMES Trial • Rivaroxaban for 18 Months vs. 6 Months in Cancer Patients With Low-Risk Pulmonary Embolism: ONCO PE Trial FS.05: Amyloid, Hypertrophic and Danon Cardiomyopathies: Targeted Therapies and Specific Populations 9:45-11 a.m. | S103BC • Danon Disease Phase 1 RP-A501 Results: The First Single-Dose Intravenous Gene Therapy With Recombinant Adeno-Associated Virus (AAV9:LAMP2B) for a Monogenic Cardiomyopathy (accepted, not confirmed at time of publication) • Mavacamten Treatment in Patients With Obstructive HCM Referred for Septal Reduction Therapy: 128-Week Results From VALOR-HCM Trial • Acoramidis Reduces AllCause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes From the ATTRibuteCM Open-Label Extension (OLE) Study • Impact of Vutrisiran on Markers of Disease Progression in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B Trial • The Prevalence of Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure: The Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations Study (SCAN-MP) • ATTR-Specific Medication in Dual Pathology Aortic Stenosis and Transthyretin Cardiac Amyloidosis FS.06: Novel Insights in Cardiovascular Interventional Outcomes 1:30-2:45 p.m. | S100A • Semaglutide Improves Cardiovascular Outcomes in Patients With a History of Coronary Artery Bypass Surgery and Overweight or Obesity: The SELECT Trial • Five-Year Results From the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial (Amulet IDE) • The Impact of Carbon Monoxide to Determine the In-Hospital Prognosis After Acute Coronary Syndrome (ADDICT-ICCU) • Quantitative Assessment of Mitral Annular Calcification Severity Predicts Outcomes in Severe Aortic Stenosis Patients Undergoing Transcatheter Aortic Valve Replacement FS.07: Incretion Modulation Is the Time Now for Standard of Care 1:30-2:45 p.m. | S103BC • Effect of Tirzepatide on Cardiac Structure and Function in Obese HFpEF: the SUMMIT CMR Substudy • Effects of Tirzepatide on the Clinical and Symptom Burden of Patients With Heart Failure and a Preserved Ejection Fraction: Results From the SUMMIT Trial • Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status or Risk in the FLOW Trial Main Events Making Great Strides: Our Journey in the Treatment of Acute Myocardial Infarction 9:45-11 a.m. | Main Event II Henning Lecture Session: Non-Traditional Risk Factors & Biomarkers of Peripheral Arterial Disease 9:45-11 a.m. | S100A Gene Therapy in the Cardiology Clinic: Ready for Prime Time? 1:30-2:45 p.m. | Main Event II Additional resource available: Gene Therapy in Cardiovascular Disease: Recent Advances and Future Directions in Science a recently released AHA Science Advisory
RkJQdWJsaXNoZXIy MjI2NjI=